Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Wiendl, H.
Butzkueven, H.
Trojano, M.
Goodin, D.
Kappos, L.
Desgrandchamps, D.
机构：
[1] Univ Wurzburg, Wurzburg, Germany
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Univ Bari, Bari, Italy
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
[6] Biogen Idec Int GmbH, Zug, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [1] Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
    Dekker, I
    Leurs, C. E.
    Hagens, M. H. J.
    van Kempen, Z. L. E.
    Kleerekooper, I
    Lissenberg-Witte, B., I
    Barkhof, F.
    Uitdehaag, B. M. J.
    Balk, L. J.
    Wattjes, M. P.
    Killestein, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 82 - 87
  • [2] TYSABRI® observational program: a long-term evaluation of safety and impact on disease activity and progression of natalizumab in relapsing-remitting MS
    Trojano, M.
    Butzkueven, H.
    Goodin, D.
    Kappos, L.
    Wiendl, H.
    Desgrandchamps, D.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S109 - S109
  • [3] Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
    Planas, Raquel
    Martin, Roland
    Sospedra, Mireia
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 25 - 33
  • [4] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [5] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [6] Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI® Observational Program (TOP)
    Kappos, L.
    Belachew, S.
    Butzkueven, H.
    Pellegrini, F.
    Trojano, M.
    Wiendl, H.
    Zhang, A.
    Desgrandchamps, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 55 - 55
  • [7] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [8] Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI® Observational Program (TOP)
    Wiendl, H.
    Kappos, L.
    Trojano, M.
    Butzkueven, H.
    Pellegrini, F.
    Belachew, S.
    Pace, A.
    Desgrandchamps, D.
    JOURNAL OF NEUROLOGY, 2010, 257 : S22 - S22
  • [9] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [10] Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort
    Bigaut, K.
    Fabacher, T.
    Kremer, L.
    Ongagna, J. -C.
    Kwiat-Kowski, A.
    Sellal, F.
    Ferriby, D.
    Courtois, S.
    Vermersch, P.
    Collongues, N.
    Zephir, H.
    De Seze, J.
    Outteryck, O.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 536 - 536
12345